Ventripoint Diagnostics Ltd. (TSXV:VPT)
0.1150
-0.0100 (-8.00%)
Jun 1, 2026, 1:28 PM EST
Ventripoint Diagnostics Revenue
In the year 2025, Ventripoint Diagnostics had annual revenue of 179.93K CAD with 89.06% growth. Ventripoint Diagnostics had revenue of 104.30K in the quarter ending December 31, 2025, with 61.69% growth.
Revenue
179.93K
Revenue Growth
+89.06%
P/S Ratio
132.70
Revenue / Employee
n/a
Employees
n/a
Market Cap
23.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 179.93K | 84.76K | 89.06% |
| Dec 31, 2024 | 95.17K | 45.99K | 93.51% |
| Dec 31, 2023 | 49.18K | -18.98K | -27.85% |
| Dec 31, 2022 | 68.17K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 36.02K | -45.01K | -55.55% |
| Dec 31, 2019 | 81.02K | 20.85K | 34.64% |
| Dec 31, 2018 | 60.18K | 21.27K | 54.68% |
| Dec 31, 2017 | 38.91K | -170.57K | -81.43% |
| Dec 31, 2016 | 209.48K | 158.18K | 308.38% |
| Dec 31, 2015 | 51.30K | -77.16K | -60.07% |
| Dec 31, 2014 | 128.45K | 57.51K | 81.05% |
| Dec 31, 2013 | 70.95K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurora Spine | 25.67M |
| Perimeter Medical Imaging AI | 2.98M |
| Cheelcare | 1.63M |
| Theralase Technologies | 816.47K |
| Conavi Medical | 778.00K |
| Frequency Exchange | 745.08K |
| MedX Health | 473.27K |
| NuGen Medical Devices | 257.95K |
Ventripoint Diagnostics News
- 7 days ago - Ventripoint Provides Videoconference Link to Annual General Meeting and Corporate Update - TheNewswire
- 9 days ago - Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement - TheNewswire
- 13 days ago - Ventripoint Issues Shares for Payment of Debenture Interest - TheNewswire
- 4 weeks ago - Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology - TheNewswire
- 4 weeks ago - Ventripoint Diagnostics Registration statement: Q4 2025 - Filings
- 4 weeks ago - Ventripoint Diagnostics Registration statement: Q4 2025 - Filings
- 4 weeks ago - Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc. - TheNewswire
- 5 weeks ago - Ventripoint Issue Shares for Payment of Debenture Interest - TheNewswire